Eisai 향후 성장

Future 기준 점검 2/6

Eisai (는) 각각 연간 13.8% 및 3.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.1% 로 예상됩니다.

핵심 정보

13.8%

이익 성장률

13.72%

EPS 성장률

Pharmaceuticals 이익 성장	8.7%
매출 성장률	3.6%
향후 자기자본이익률	7.12%
애널리스트 커버리지	Good
마지막 업데이트	08 Jun 2026

최근 향후 성장 업데이트

분석 기사 • Feb 11

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Investors in Eisai Co., Ltd. ( TSE:4523 ) had a good week, as its shares rose 8.9% to close at JP¥4,836 following the...

분석 기사 • Nov 09

Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Eisai Co., Ltd. ( TSE:4523 ) shareholders are probably feeling a little disappointed, since its shares fell 4.0% to...

분석 기사 • Aug 08

Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Eisai Co., Ltd. ( TSE:4523 ) just released its quarterly report and things are looking bullish. It was overall a...

Recent updates

내러티브 업데이트 • Jun 03

4523: Future Alzheimer Regulatory Progress Will Likely Just Support Current Valuation

Narrative update on Eisai Analysts have trimmed Eisai's price target from ¥3,674.94 to ¥3,500.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple, while also factoring in recent sector readthroughs from broader pharmaceutical research coverage. What’s in the News Eisai and BioArctic highlight Leqembi, with reported sales of JPY 143.5b targeted for fiscal 2026 and a simulation presented for around JPY 300b in fiscal 2028, alongside a EUR 20m milestone payment to BioArctic after sales passed EUR 500m in fiscal 2025 (source: Eisai/BioArctic news).

내러티브 업데이트 • May 19

4523: Alzheimer’s And Oncology Pipeline Will Support Steady Future Returns

Analysts have nudged their price target on Eisai higher to about ¥5,077 from roughly ¥5,009, citing updated assumptions that include a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a marginally higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as consistent with Eisai executing broadly in line with updated revenue and margin assumptions, which supports the revised P/E multiple being applied.

내러티브 업데이트 • May 02

4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Earnings Quality And Future Share Returns

Analysts have maintained their Eisai price target at ¥6,200, citing slightly higher revenue growth assumptions, a modestly lower profit margin outlook, and an updated future P/E of about 19x as the main reasons for keeping their view unchanged. Analyst Commentary Analysts keeping the Eisai price target at ¥6,200 are signaling that current assumptions on revenue growth, margins, and a future P/E of about 19x already capture what they see as the key drivers for the stock.

내러티브 업데이트 • Apr 17

4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price

Analysts have adjusted their price target on Eisai to ¥3,674.94 from ¥3,600, reflecting updated assumptions around more measured revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News Eisai and MSD submitted a Japanese application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and no new safety signals (Key Developments).

내러티브 업데이트 • Apr 03

4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook

Analysts have trimmed their Eisai price target slightly to ¥5,009 from ¥5,012, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What's in the News Eisai and MSD submitted a Japan application for Lenvima in combination with Welireg for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy, supported by Phase 3 LITESPARK-011 data showing a 30% reduction in risk of disease progression or death versus cabozantinib and a safety profile consistent with each monotherapy (Product-Related Announcements).

내러티브 업데이트 • Mar 20

4523: Future Alzheimer Dosing Filings Will Still Not Support Current Valuation

Analysts have kept their ¥3,600 price target on Eisai steady, pointing to slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a lower assumed future P/E as the key drivers behind the updated view. What's in the News The U.S. FDA has granted Priority Review to Eisai's supplemental Biologics License Application for Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease, with a PDUFA action date set for May 24, 2026 (Key Developments).

내러티브 업데이트 • Mar 05

4523: Future Alzheimer Dosing Submissions Will Not Justify Current Share Price

Analysts have kept Eisai's fair value estimate steady at ¥3,600 per share. They cite updated assumptions for slightly higher revenue growth and profit margins, alongside a more conservative future P/E.

내러티브 업데이트 • Feb 19

4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Margins And Future Share Returns

Analysts have kept their Eisai price target steady at ¥6,200. The latest update reflects slightly softer revenue growth expectations at 7.31%, a modestly higher profit margin outlook of 11.14%, and a small adjustment in assumed future P/E to 18.03x.

분석 기사 • Feb 17

Eisai's (TSE:4523) Shareholders Have More To Worry About Than Only Soft Earnings

Eisai Co., Ltd.'s ( TSE:4523 ) stock showed strength, with investors undeterred by its weak earnings report. We think...

분석 기사 • Feb 11

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Investors in Eisai Co., Ltd. ( TSE:4523 ) had a good week, as its shares rose 8.9% to close at JP¥4,836 following the...

분석 기사 • Feb 09

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 1st of June. This means the annual payment is 3.6% of...

내러티브 업데이트 • Feb 05

4523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns

Analysts have lifted their fair value estimate for Eisai to ¥6,200 from ¥6,000, citing updated assumptions that combine a slightly higher discount rate and lower revenue growth with a stronger projected profit margin and a lower future P/E multiple. What's in the News Eisai and BioArctic submitted a Marketing Authorisation Variation to the European Medicines Agency for once every four weeks IV maintenance dosing of lecanemab, following an initial once every two weeks regimen for 18 months in early Alzheimer’s disease.

분석 기사 • Jan 26

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. ( TSE:4523 ) will pay a dividend of ¥80.00 on the 1st of June. The dividend yield will be 3.5% based on...

내러티브 업데이트 • Jan 22

4523: Long-Term Alzheimer Injection Shift Will Not Sustain Current Share Price

Analysts have kept Eisai's fair value estimate steady at ¥3,600.0, highlighting modest adjustments to revenue growth, profit margins and future P/E assumptions as they fine tune their price targets rather than rethink the core thesis. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous Leqembi autoinjector for early Alzheimer's treatment, with similar filings submitted to the U.S. FDA and Japan's PMDA, targeting at home weekly dosing as an alternative to current IV regimens (Key Developments).

내러티브 업데이트 • Jan 08

4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price

Analysts have maintained their price target for Eisai at ¥3,600, citing updated assumptions for revenue growth, profit margins, and future P/E that continue to support the existing valuation framework. What's in the News Regulators in China accepted Eisai's Biologics License Application for a subcutaneous autoinjector formulation of Leqembi for early Alzheimer’s disease, with similar initiation dosing applications also submitted in the U.S. and Japan (Product related announcements) Eisai and partners reported clinical and modeling data at the CTAD conference suggesting long term lecanemab treatment was associated with delayed progression from mild cognitive impairment to more advanced Alzheimer’s stages, with subcutaneous dosing showing drug exposure comparable to intravenous administration (Product related announcements) Multiple filings were completed with the U.S. FDA for Leqembi Iqlik subcutaneous initiation dosing, following earlier approval for subcutaneous maintenance dosing.

분석 기사 • Jan 06

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 1st of...

내러티브 업데이트 • Dec 19

4523: Future Alzheimer Data Will Not Justify Current Share Price

Analysts have raised their price target on Eisai to 3,600.00, reflecting improved expectations for revenue growth and slightly stronger profit margins, despite a modest uptick in the assumed discount rate and a marginally lower future P/E multiple. What's in the News New long term data for Alzheimer therapy Leqembi suggest early and continued lecanemab treatment could delay progression from mild cognitive impairment to moderate Alzheimer disease by up to 8.3 years, which supports sustained use and earlier initiation (CTAD conference presentations).

내러티브 업데이트 • Dec 05

4523: Future Alzheimer’s Pipeline And At Home Treatments Will Support Steady Outlook

Analysts have slightly reduced their price target on Eisai, trimming fair value by about $15 per share to approximately $5,012. They cited marginally lower long term growth and profitability assumptions, while maintaining a similar forward earnings multiple.

분석 기사 • Dec 03

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend on the 1st of June, with investors...

내러티브 업데이트 • Nov 21

4523: Upcoming Clinical Data And Regulatory Milestones Will Support Steady Long-Term Outlook

Analysts have maintained their price target for Eisai at ¥5,026.92, citing only minor adjustments to revenue growth and profit margin estimates. These adjustments did not significantly influence their overall valuation.

분석 기사 • Nov 19

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 1st of June. Based on...

분석 기사 • Nov 09

Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Eisai Co., Ltd. ( TSE:4523 ) shareholders are probably feeling a little disappointed, since its shares fell 4.0% to...

내러티브 업데이트 • Nov 07

4523: Upcoming Regulatory Approvals And Product Launches Will Drive Shares Higher

Narrative Update on Eisai: Analyst Price Target Revision Analysts have maintained their price target for Eisai at ¥5,026.92, citing slightly stronger revised revenue growth forecasts and a modest increase in the discount rate as underlying factors in their valuation assessment. What's in the News Health Canada issued a Notice of Compliance with conditions for LEQEMBI® (lecanemab), making it the first treatment for early Alzheimer's disease that targets an underlying cause to be authorized in Canada.

내러티브 업데이트 • Oct 24

Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects

Narrative Update on Eisai Analysts have raised Eisai’s price target modestly from ¥4,988 to ¥5,027. This change reflects slight improvements in revenue growth and profit margin assumptions.

내러티브 업데이트 • Oct 10

Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Eisai Co., Ltd. ( TSE:4523 ) just released its quarterly report and things are looking bullish. It was overall a...

분석 기사 • Jul 23

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Eisai Co., Ltd.'s ( TSE:4523 ) investors are due to receive a payment of ¥80.00 per share on 19th of November. Based on...

분석 기사 • Jul 09

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

The board of Eisai Co., Ltd. ( TSE:4523 ) has announced that it will pay a dividend of ¥80.00 per share on the 19th of...

분석 기사 • Jun 22

Eisai's (TSE:4523) Solid Profits Have Weak Fundamentals

Eisai Co., Ltd. ( TSE:4523 ) announced strong profits, but the stock was stagnant. Our analysis suggests that this...

이익 및 매출 성장 예측

TSE:4523 - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2029	957,334	68,359	63,563	97,678	11
3/31/2028	936,547	64,947	44,402	74,678	13
3/31/2027	890,143	56,267	62,287	84,951	12
3/31/2026	825,378	38,558	20,156	61,323	N/A
12/31/2025	808,186	42,756	60,722	86,550	N/A
9/30/2025	804,390	49,369	25,213	51,509	N/A
6/30/2025	803,022	50,325	14,306	39,792	N/A
3/31/2025	789,400	46,432	7,148	30,117	N/A
12/31/2024	791,660	58,792	1,672	18,856	N/A
9/30/2024	753,221	40,970	7,189	27,613	N/A
6/30/2024	733,845	32,648	13,901	34,771	N/A
3/31/2024	741,751	42,406	31,170	55,993	N/A
12/31/2023	749,460	45,421	35,701	61,925	N/A
9/30/2023	759,329	48,096	20,569	46,335	N/A
6/30/2023	757,075	48,874	-20,313	6,924	N/A
3/31/2023	744,402	55,432	-36,331	-1,772	N/A
12/31/2022	737,098	26,705	-17,149	18,648	N/A
9/30/2022	752,500	32,233	-8,913	30,329	N/A
6/30/2022	741,594	32,690	94,326	135,806	N/A
3/31/2022	756,226	47,954	77,123	117,590	N/A
12/31/2021	712,935	57,311	85,128	124,927	N/A
9/30/2021	691,250	62,508	80,215	123,618	N/A
6/30/2021	679,253	59,855	8,589	49,533	N/A
3/31/2021	645,942	42,119	35,709	73,853	N/A
12/31/2020	707,888	93,682	52,352	95,670	N/A
9/30/2020	713,400	120,571	77,080	112,990	N/A
6/30/2020	707,203	124,523	81,101	116,904	N/A
3/31/2020	695,621	121,767	52,556	102,782	N/A
12/31/2019	661,646	96,659	N/A	72,461	N/A
9/30/2019	631,974	57,725	N/A	62,240	N/A
6/30/2019	643,531	72,747	N/A	87,299	N/A
3/31/2019	642,834	63,386	N/A	103,714	N/A
12/31/2018	627,367	63,714	N/A	171,330	N/A
9/30/2018	625,106	65,679	N/A	186,973	N/A
6/30/2018	611,499	54,347	N/A	165,689	N/A
3/31/2018	600,054	51,845	N/A	149,649	N/A
12/31/2017	569,814	29,048	N/A	72,041	N/A
9/30/2017	554,276	30,269	N/A	61,644	N/A
6/30/2017	544,027	29,425	N/A	76,929	N/A
3/31/2017	539,097	39,358	N/A	75,851	N/A
12/31/2016	530,696	55,031	N/A	76,725	N/A
9/30/2016	542,313	71,812	N/A	78,627	N/A
6/30/2016	545,602	69,227	N/A	69,710	N/A
3/31/2016	547,922	54,933	N/A	95,617	N/A
12/31/2015	566,435	44,886	N/A	96,347	N/A
9/30/2015	554,912	43,871	N/A	82,653	N/A
6/30/2015	554,885	43,021	N/A	89,212	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 4523 의 연간 예상 수익 증가율(13.8%)이 saving rate(0.8%)보다 높습니다.

수익 vs 시장: 4523 의 연간 수익(13.8%)이 JP 시장(9.3%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: 4523 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 4523 의 수익(연간 3.6%)이 JP 시장(연간 6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: 4523 의 수익(연간 3.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 4523의 자본 수익률은 3년 후 7.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/11 11:10
종가	2026/06/11 00:00
수익	2026/03/31
연간 수익	2026/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Eisai Co., Ltd.는 20명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Eisai 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Eisai Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026 (April 2026 to March 2027)

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Eisai Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates fall by 11%

Recent updates

4523: Future Alzheimer Regulatory Progress Will Likely Just Support Current Valuation

Eisai Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026 (April 2026 to March 2027)

Eisai Eyes Strong Leqembi Growth as FDA and EU Decisions Approach

4523: Alzheimer’s And Oncology Pipeline Will Support Steady Future Returns

New major risk - Dividend sustainability

Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2026

Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026

4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Earnings Quality And Future Share Returns

Eisai Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026

4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price

4523: Alzheimer’s Franchise And Oncology Pipeline Will Support Steady Long Term Outlook

Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in Japan

Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab

Upcoming dividend of JP¥80.00 per share

Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States

4523: Future Alzheimer Dosing Filings Will Still Not Support Current Valuation

Now 20% undervalued

4523: Future Alzheimer Dosing Submissions Will Not Justify Current Share Price

Now 20% undervalued

4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Margins And Future Share Returns

Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for Narcolepsy

Eisai's (TSE:4523) Shareholders Have More To Worry About Than Only Soft Earnings

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Third quarter 2026 earnings: EPS in line with analyst expectations despite revenue beat

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

4523: Future Margin Upside From Subcutaneous Alzheimer’s Treatment Will Support Higher Returns

Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDA

Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review

4523: Long-Term Alzheimer Injection Shift Will Not Sustain Current Share Price

4523: Future Alzheimer Subcutaneous Rollout Will Not Support Current Share Price

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's Disease

4523: Future Alzheimer Data Will Not Justify Current Share Price

4523: Future Alzheimer’s Pipeline And At Home Treatments Will Support Steady Outlook

Eisai Presents the Latest Findings on Time Savings with Continued Treatment with Leqembi

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Eisai Co., Ltd. Presents New Data on Anti-Tau Antibody Etalanetug (E2814) At CTAD 2025

Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting Dose

Eisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

4523: Upcoming Clinical Data And Regulatory Milestones Will Support Steady Long-Term Outlook

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease Conference

First half dividend of JP¥80.00 announced

Eisai Announces Leqembi Approval for IV Maintenance Treatment in the United Kingdom

Eisai Co., Ltd. Enters into Settlement Agreement with Torrent Pharmaceuticals Ltd

Eisai Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

4523: Upcoming Regulatory Approvals And Product Launches Will Drive Shares Higher

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Cancer

Merck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMA

Health Canada Grants Authorization for Leqembi (Lecanemab)

Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity

Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's Disease

Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study

Eisai Announces Leqembi Approval for IV Maintenance Treatment in China

Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in Australia

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Upcoming dividend of JP¥80.00 per share

Eisai Co., Ltd. Announces Etalanetug Granted FDA Fast Track Designation

Alzheimer's Biomarker Adoption And Global Rollout Will Fuel Future Opportunity

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025